Formulary
Atorvastatin: Uses, Dosing, Side Effects and Indian Brand Names
Atorvastatin is the most potent commonly used statin, reducing LDL-C by up to 54%, with extensive trial evidence supporting its use in cardiovascular risk reduction, diabetes, and secondary prevention.
MedNext Academy | 4 min read
Clinically reviewed by Awaiting clinical review
Atorvastatin: Uses, Dosing, Side Effects and Indian Brand Names
Atorvastatin is the most potent commonly used statin, reducing LDL-C by up to 54%, with extensive trial evidence supporting its use in cardiovascular risk reduction, diabetes, and secondary prevention.
NEET PG High-Yield: Most potent commonly used statin. Long half-life (14 h + active metabolites) -- can be taken any time of day (unlike simvastatin which is bedtime only because cholesterol synthesis peaks at night and simvastatin has a 2-hour half-life). CYP3A4 metabolism. Simvastatin dose cap with amlodipine (20 mg max) but no such cap with atorvastatin. Category X in pregnancy. Rhabdomyolysis: myoglobin renal failure. Pleiotropic effects beyond lipid lowering.
Clinical overview
Atorvastatin is the most widely prescribed statin globally and in India, with an extensive evidence base from trials including CARDS (diabetes), SPARCL (stroke prevention), TNT (intensive lipid lowering), and PROVE-IT (ACS). It is a synthetic statin with the highest potency for LDL-C reduction among commonly used statins, capable of reducing LDL-C by 38-54% depending on dose. Unlike simvastatin and lovastatin, atorvastatin has a long half-life (approximately 14 hours) and its active metabolites extend the effective duration to over 20 hours, allowing flexible dosing at any time of day rather than strictly at bedtime. Atorvastatin is metabolised by CYP3A4 but is less susceptible to drug interactions than simvastatin because it does not undergo extensive first-pass extraction. Myopathy and rhabdomyolysis are the most feared adverse effects; risk is increased by concurrent use of CYP3A4 inhibitors, fibrates (particularly gemfibrozil), and high doses. New-onset diabetes mellitus is a class effect of statins, with the absolute risk being approximately 1 additional case per 1000 patients per year of treatment -- far outweighed by cardiovascular benefit in indicated populations. Hepatotoxicity is rare; routine liver function monitoring is no longer mandated by most guidelines, but baseline ALT should be checked. In India, atorvastatin is available at very low cost thanks to robust generic competition, and FDC formulations with aspirin, clopidogrel, and antihypertensives are extremely popular.
Pharmacological class
Atorvastatin belongs to the HMG-CoA Reductase Inhibitors (Statins) class. Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis (mevalonate pathway). Reduced intracellular cholesterol upregulates LDL receptor expression on hepatocytes, increasing LDL-C clearance from plasma. Additionally has pleiotropic effects including plaque stabilisation, improved endothelial function, and anti-inflammatory activity.
Indian brand names and formulations
Available as: Atorva (Zydus), Lipitor (Pfizer/Biocon), Atocor (Dr. Reddy's), Storvas (Sun Pharma).
Tablets: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg. FDC with aspirin (Atorva-ASP), clopidogrel + aspirin (Atorva-C), ezetimibe (Atorva-EZ), fenofibrate, amlodipine, and telmisartan.
Regulatory status
Atorvastatin is classified under Schedule H in India under the Drugs and Cosmetics Act, 1940. Prescription-only. Listed on NLEM. One of the highest-volume prescriptions in Indian cardiology practice.
Indications
- Primary hypercholesterolaemia and mixed dyslipidaemia
- Secondary prevention of cardiovascular events (post-MI, post-stroke, stable CAD)
- Primary prevention in high-risk individuals (diabetes, high ASCVD risk score)
- Familial hypercholesterolaemia
- Acute coronary syndrome (high-intensity statin: 40-80 mg)
Dosing
Adults: 10-20 mg once daily for moderate-intensity therapy; 40-80 mg once daily for high-intensity therapy. Can be taken at any time of day. No dose adjustment for renal impairment. Start with 10 mg in elderly or when using CYP3A4 inhibitors. Maximum 20 mg with concurrent amiodarone.
Contraindications
- Active liver disease or unexplained persistent transaminase elevation (>3x ULN)
- Pregnancy and lactation (Category X -- cholesterol is essential for foetal development)
- Concomitant use with strong CYP3A4 inhibitors at high statin doses (e.g., itraconazole, clarithromycin)
Adverse effects
- Myalgia (most common reason for discontinuation, ~5-10% of patients; actual statin-attributable myalgia is lower per SAMSON trial)
- Elevated transaminases (dose-dependent, >3x ULN in <1%)
- Rhabdomyolysis (rare but potentially fatal; CK >10x ULN with myoglobinuria and renal failure)
- New-onset diabetes mellitus (class effect, ~1 extra case per 1000 patients per year)
- GI disturbances (nausea, diarrhoea, constipation)
- Headache and insomnia
Drug interactions
- CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, erythromycin, HIV protease inhibitors, grapefruit juice in large quantities): increased atorvastatin levels and myopathy risk
- Gemfibrozil: significantly increased rhabdomyolysis risk (fenofibrate is safer to combine)
- Cyclosporine: limit atorvastatin to 10 mg daily
- Warfarin: may increase INR; monitor closely when initiating or changing statin dose
- Colchicine: additive myopathy risk
Pregnancy and lactation
Category X. Absolutely contraindicated. Cholesterol is essential for foetal membrane and steroid hormone synthesis. Discontinue at least 1-3 months before planned conception.
Exam-style clinical scenario
A 52-year-old man is admitted with STEMI. After primary PCI, what intensity of statin therapy is recommended regardless of baseline LDL-C? High-intensity atorvastatin 40-80 mg -- guidelines recommend high-intensity statin in all ACS patients irrespective of baseline lipid levels (pleiotropic plaque-stabilising effects).
Cost in India
Rs 30-100 for a strip of 10 tablets (10 mg). High-intensity 40 mg: Rs 60-150 per strip. Generic prices have fallen dramatically.
Clinical governance
Author: MedNext Editorial Team. Clinical reviewer: Awaiting clinical review. Jurisdiction: India (Drugs and Cosmetics Act, 1940). Sources: CIMS India, Indian Pharmacopoeia. Publication state: Awaiting clinical review. Correction: Report errors at support@mednext.academy.
Frequently Asked Questions
Why can atorvastatin be taken at any time but simvastatin must be taken at night?
Cholesterol synthesis peaks during the night. Simvastatin has a short half-life (~2 hours), so it must be taken at bedtime to align peak drug levels with peak cholesterol synthesis. Atorvastatin has a much longer effective half-life (~14 hours for parent compound, and its active metabolites extend this to 20-30 hours), providing round-the-clock HMG-CoA reductase inhibition regardless of when it is taken.
Is the risk of new-onset diabetes a reason to avoid statins?
No. The absolute risk is approximately 1 additional case of diabetes per 1000 patients per year of statin therapy. In contrast, statins prevent approximately 5-10 major cardiovascular events per 1000 patients per year in secondary prevention. The cardiovascular benefit far outweighs the diabetes risk in patients who meet statin therapy criteria.
What is the simvastatin dose cap with amlodipine and why does it not apply to atorvastatin?
Amlodipine inhibits CYP3A4, increasing simvastatin levels. Because simvastatin undergoes extensive CYP3A4-mediated first-pass metabolism, this interaction is clinically significant, and simvastatin is capped at 20 mg with amlodipine. Atorvastatin is less susceptible because it has lower first-pass extraction, so the interaction is not clinically significant enough to warrant a dose cap.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
Test yourself on Atorvastatin
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary